C Wenneberg1,2,3, B Y Glenthøj2, L B Glenthøj1,2, B Fagerlund2, K Krakauer1,2,3, T D Kristensen1,2, C Hjorthøj1,4, R A E Edden5, B V Broberg2, K B Bojesen2, E Rostrup2,3, M Nordentoft1. 1. Copenhagen Research Center for Mental Health, University of Copenhagen, Copenhagen, Denmark. 2. Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Copenhagen, Denmark. 3. Functional Imaging Unit, FIUNIT, Department of Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, Denmark. 4. Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 5. Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Cerebral glutamate and gamma-aminobutyric acid (GABA) levels might predict clinical outcome in individuals at ultrahigh risk (UHR) for psychosis but have previously primarily been investigated in smaller cohorts. We aimed to study whether baseline levels of glutamate and GABA in anterior cingulate cortex (ACC) and glutamate in thalamus could predict remission status and whether baseline metabolites differed in the remission versus the nonremission group. We also investigated the relationship between baseline metabolite levels and severity of clinical symptoms, functional outcome, and cognitive deficits at follow-up. METHODS: About 124 UHR individuals were recruited at baseline. In this, 74 UHR individuals were clinically and cognitively assessed after 12 months, while remission status was available for 81 (25 remission/56 nonremission). Glutamate and GABA levels were assessed at baseline using 3 T proton magnetic resonance spectroscopy. Psychopathology, symptom severity, and remission were assessed with the Comprehensive Assessment of At-Risk Mental States and Clinical Global Impression and functional outcome with the Social and Occupational Functioning Assessment Scale. Cognitive function was estimated with the Cambridge Neuropsychological Test Automated Battery. RESULTS: There were no differences between baseline glutamate and GABA levels in subjects in the nonremission group compared with the remission group, and baseline metabolites could not predict remission status. However, higher baseline levels of GABA in ACC were associated with clinical global improvement (r = -0.34, N = 51, p = 0.01) in an explorative analysis. CONCLUSIONS: The variety in findings across studies suggests a probable multifactorial influence on clinical outcome in UHR individuals. Future studies should combine multimodal approaches to attempt prediction of long-term outcome.
BACKGROUND: Cerebral glutamate and gamma-aminobutyric acid (GABA) levels might predict clinical outcome in individuals at ultrahigh risk (UHR) for psychosis but have previously primarily been investigated in smaller cohorts. We aimed to study whether baseline levels of glutamate and GABA in anterior cingulate cortex (ACC) and glutamate in thalamus could predict remission status and whether baseline metabolites differed in the remission versus the nonremission group. We also investigated the relationship between baseline metabolite levels and severity of clinical symptoms, functional outcome, and cognitive deficits at follow-up. METHODS: About 124 UHR individuals were recruited at baseline. In this, 74 UHR individuals were clinically and cognitively assessed after 12 months, while remission status was available for 81 (25 remission/56 nonremission). Glutamate and GABA levels were assessed at baseline using 3 T proton magnetic resonance spectroscopy. Psychopathology, symptom severity, and remission were assessed with the Comprehensive Assessment of At-Risk Mental States and Clinical Global Impression and functional outcome with the Social and Occupational Functioning Assessment Scale. Cognitive function was estimated with the Cambridge Neuropsychological Test Automated Battery. RESULTS: There were no differences between baseline glutamate and GABA levels in subjects in the nonremission group compared with the remission group, and baseline metabolites could not predict remission status. However, higher baseline levels of GABA in ACC were associated with clinical global improvement (r = -0.34, N = 51, p = 0.01) in an explorative analysis. CONCLUSIONS: The variety in findings across studies suggests a probable multifactorial influence on clinical outcome in UHR individuals. Future studies should combine multimodal approaches to attempt prediction of long-term outcome.
Authors: Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby Journal: Aust N Z J Psychiatry Date: 2005 Nov-Dec Impact factor: 5.744
Authors: M J Hilsenroth; S J Ackerman; M D Blagys; B D Baumann; M R Baity; S R Smith; J L Price; C L Smith; T L Heindselman; M K Mount; D J Holdwick Journal: Am J Psychiatry Date: 2000-11 Impact factor: 18.112
Authors: Ruth L O'Gorman; Lars Michels; Richard A Edden; James B Murdoch; Ernst Martin Journal: J Magn Reson Imaging Date: 2011-05 Impact factor: 4.813
Authors: Paul G Mullins; David J McGonigle; Ruth L O'Gorman; Nicolaas A J Puts; Rishma Vidyasagar; C John Evans; Richard A E Edden Journal: Neuroimage Date: 2012-12-13 Impact factor: 6.556
Authors: Barnaby Nelson; Hok Pan Yuen; Stephen J Wood; Ashleigh Lin; Daniela Spiliotacopoulos; Annie Bruxner; Christina Broussard; Magenta Simmons; Debra L Foley; Warrick J Brewer; Shona M Francey; G Paul Amminger; Andrew Thompson; Patrick D McGorry; Alison R Yung Journal: JAMA Psychiatry Date: 2013-08 Impact factor: 21.596
Authors: Gemma Modinos; Fatma Simsek; Jamie Horder; Matthijs Bossong; Ilaria Bonoldi; Matilda Azis; Jesus Perez; Matthew Broome; David J Lythgoe; James M Stone; Oliver D Howes; Declan G Murphy; Anthony A Grace; Paul Allen; Philip McGuire Journal: Int J Neuropsychopharmacol Date: 2018-02-01 Impact factor: 5.176
Authors: Courtney J Wright; Katherine M Rentschler; Nathan T J Wagner; Ashley M Lewis; Sarah Beggiato; Ana Pocivavsek Journal: Front Psychiatry Date: 2021-09-17 Impact factor: 4.157
Authors: Tineke Grent-'t-Jong; Ruchika Gajwani; Joachim Gross; Andrew I Gumley; Stephen M Lawrie; Matthias Schwannauer; Frauke Schultze-Lutter; Stephen R Williams; Peter J Uhlhaas Journal: Front Psychiatry Date: 2022-03-29 Impact factor: 4.157